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Summary SR2508 sensitises certain hypoxic tumour cells in vitro and in vivo to the cytotoxic action of
radiation and alkylating agents. The mechanism of sensitisation may derive in part from depletion of
glutathione (GSH) and possibly inhibition of GSH-dependent enzymes in target cells. We treated 46 evaluable
patients with cyclophosphamide 750-1000 mg m-2 followed by SR2508 at eight dose levels ranging from 2.5
to 15.0 g m-2. Each patient received SR2508 as a single agent initially, followed a week later by the
combination of cyclophosphamide and SR2508. Initially, myelsuppression was the major toxicity; potentiation
of cyclophosphamide-induced leukopenia by SR2508 required a dose reduction of cyclophosphamide to
750 mg m-2 at SR2508 doses above 7.2 g m-2. At doses above 9.4 g m-2 an acute syndrome of muscle pains
and painful paresthesias of the extremities lasting 12-24 h was observed to occur with increasing severity. This
side-effect was intolerable in two of three patients treated at 15.0 g m-2. The only other reproducible side-effect
was nausea and vomiting which was controllable with antiemetics. Plasma and urine SR2508 concentrations
were measured by HPLC in 45 patients. Plasma elimination curves fit a 2-compartment model. The mean
terminal half-life at each dose level ranged from 5.1 -5.8 h. The mean area under the plasma concentration-
time curve was linearly related to dose, and mean total body clearance ranged from
46.6-94.0 ml-' min'm-2; renal clearance accounted for 65.7-79.3%. Pretreatment with cyclophosphamide
did not influence the kinetics of SR2508 in individual patients. Examination of the glutathione content of
peripheral mononuclear cells and tumour samples showed that depletion to below 50% of control occurred in
the majority of patients. GSH transferase inhibition occurred with a similar time-course, but to a lesser extent.
These data suggest that the further evaluation of this regimen should be conducted with SR2508 administra-
tion preceding that of cyclophosphamide and that its evaluation in cyclophosphamide-sensitive tumours is
warranted.
Resistance of the common slow-growing solid tumours to
current chemotherapeutic strategies appears in part to be a
consequence of the abnormal metabolic environment of solid
tumours. It is proposed that the disordered vascular develop-
ment in the growing tumor mass results in a proportion of
cells being remote from capillaries; the increased diffusion
distance leads of hypoxia, low concentrations of glucose and
other nutrients, and reduced cellular pH (Thomlinson &
Gray, 1955). Hypoxic cells are resistant both to radiation and
to electrophilic cytotoxic drugs (Sutherland, 1988; Crabtree &
Cramer, 1933). The proportion of hypoxic cells in a tumour
is in part a function of tumour size, but even small tumours
(1 mm in diameter) may have radiobiologically-defined
hypoxic fractions ranging from 10-30%. The tumour types
in which significant hypoxic fractions have been identified
include all of the common solid tumours especially lung,
colon, head and neck and breast cancers (Rockwell &
Moulder, 1990; Adams & Stratford, 1986).
SR2508 (etanidazole, NSC 301467) is a 2-nitroimidazole,
one of a series of 'oxygen mimetic' drugs which have been
evaluated recently in clinical and preclinical studies (reviewed
in Adams & Stratford, 1986, and Coleman et al., 1988). In
addition to sensitising hypoxic cells to radiation, the 2-
nitroimidazoles restore the sensitivity of hypoxic cells to
cytotoxic drugs in vitro and in vivo. This effect was first
demonstrated by Clement et al., 1980 and Rose et al., 1980
and is particularly marked for alkylating agents.
Misonidazole increased the antitumour activity of melphalan
and of cyclophosphamide by factors of 2.2 and 1.8 respec-
tively, while myelotoxicity was increased only by 1.2 and
1.3-fold (Law et al., 1981; Hirst et al., 1984). At equimolar
doses, SR2508 enhances the activity of cyclophosphamide
and melphalan as effectively as misonidazole (Hirst et al.,
1984). SR2508 was synthesised as a less lipophilic congener
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of misonidazole, since the neurotoxicity of nitroimidazoles is
directly related to their lipophilicity, and misonidazole pro-
duced neurotoxicity at doses that yielded plasma concentra-
tions insufficient for sensitisation (Brown & Workman, 1980).
In the preclinical in vivo study of Clement and colleagues, the
maximum sensitising efficacy increased both with the dose of
cyclophosphamide and that of the nitroimidazole (Clement et
al., 1980). Therefore a determination of the maximum
tolerated dose of SR2508 in a dose-escalating phase I study
was undertaken.
Several mechanisms have been proposed to account for the
chemosensitising effects of 2-nitroimidazoles (Mulcahy, 1986;
Taylor et al., 1984; Taylor et al., 1983; Murray & Meyn,
1984, and Roizen-Towle et al., 1984). Potentiation of
alkylator-induced DNA damage has been identified through
the use of alkaline elution (Taylor et al., 1983). An inhibitory
effect on DNA repair has been postulated but not proven
(Taylor et al., 1983). Others have suggested that an effect
upon the pharmacokinetics of the alkylating agent may
account for the sensitisation observed in vivo (Hinchcliffe et
al., 1983). The nitroimidazoles may themselves be cytotoxic
to cells under conditions of hypoxia; drug treatment-
associated DNA strand breaks have been described, and
binding of labelled SR2508 to DNA is reported (Smith,
1984).
The early studies of 2-nitroimidazoles showed that they
depleted cells of glutathione (GSH) (Varnes et al. pp.
121-126, 1990). Recent work has shown that GSH depletion
may be an important means of reversing resistance to
alkylating agents and platinum compounds (Ozols et al.,
1990). In addition, there is some evidence that 2-nitro-
imidazoles inhibit glutathione transferases, overexpression of
which is associated with alkylating agent resistance (Kumar
& Weiss, 1986, and Wang & Tew, 1985). Thus with the
potential to address resistance on the basis of two distinct
mechanisms, it was important to study further the effects of
SR2508 on these pathways in vivo.
The initial clinical trials of SR2508 as a radiosensitiser
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indicated that total doses substantially higher than those of
misonidazole could be administered (Coleman et al., 1986).
These studies did not however characterise the maximum
tolerated single dose of the sensitiser. The present study was
designed to (1) establish the maximum tolerated dose of
SR2508 in combination with cyclophosphamide; (2) identify
acute dose-limiting toxicities; (3) describe the pharmaco-
kinetics of SR2508 at these doses; and (4) determine the
effects on GSH levels and GST activity in the peripheral
mononuclear cells, red cells, and where possible, tumour cells
of patients treated with these drugs.
The major issue in designing an initial regimen of SR2508
in combination with cyclophosphamide was the schedule of
drug administration. Preclinical in vivo studies had produced
conflicting results concerning the necessity for preincubation.
Siemann and colleagues (1986) had shown that the optimal
schedule appeared to be when the alkylating agent (CCNU,
melphalan) and the sensitiser (misonidazole, SR 2508) were
given close to the same time, even though in some tumours
preincubation with a sensitiser was more effective. On the
other hand, Clement et al., 1980 showed that in the M5076
murine model, a two-fold increase in activity resulted when
the misonidasole and cyclophosphamide were administered
close to simultaneously. In the study conducted at Fox Chase
Cancer Center, we elected to schedule the maximum plasma
alkylating activity and maximum sensitiser levels at approx-
imately the same time, and to perform biochemical measure-
ments which could guide us to future schedule selection.
Thus to allow for hepatic activation of cyclophosphamide,
administration of the alkylator preceded that of SR2508 by
4 h. In addition, to describe the pharmacokinetics of SR2508
separately from cyclophosphamide, each patient received a
single dose of SR2508 one week before the combination was
administered.
Materials and methods
Patient population
Patients eligible for this study had a histologic diagnosis of
cancer, and had exhausted the standard therapeutic options
for their disease. They had recovered from all toxicity of
prior treatment and had not had prior chemotherapy or
radiation therapy within four weeks of entry to the study.
They were aged > 18, and had an ECOG performance status
of 0-2. They had adequate bone marrow (white cell
count > 3500 cells mm-3, platelets > 100,000 mm-3), liver
(bilirubin < 2 mg dl-'), and kidney (creatinine < 1.5 mg
dl-') function. Patients with clinical evidence of peripheral
neuropathy, or those who had prior treatment with vinca
alkaloids, were not eligible. All patients gave written in-
formed consent in accordance with Federal, State, and Insti-
tutional guidelines.
Before beginning therapy, a full history and physical
examination, complete blood count, biochemical profile,
urinalysis, electrocardiogram, and chest x-ray were per-
formed. Patients were monitored with weekly blood counts
and biochemical profiles, and clinical examinations on each
course. Doses were reduced if necessary based on toxicity;
doses were not escalated within patients. Results are reported
using the consensus toxicity criteria (Cancer Therapy Evalua-
tion Program, National Cancer Institute, Bethesda, Mary-
land, 1988). Patients with measurable disease were evaluated
(usually by scan or x-ray) every other course; those with
stable disease or better were continued on therapy. Response
criteria were standard (Miller et al., 1981).
Treatment plan
SR2508 was supplied by the National Cancer Institute,
Bethesda, Maryland, in 10ml vials containing 1 gm of a
white lyophilised powder. Vials were reconstituted with 0.9%
sodium chloride, and further with either 5% dextrose injec-
tion, U.S.P. or 0.9% sodium chloride to yield a concentra-
tion no greater than 20 mg ml-'. Higher concentrations were
found to result in pain at the injection site radiating prox-
imally along the vein. The appropriate volume was admini-
stered IV as a zero order infusion over 30 or 60 min. Drug
administration and Pharmacokinetic sampling were per-
formed in the Mary S. Schinagl Clinical Pharmacology Unit
at Fox Chase Cancer Center.
Study design
The design of the study called for an initial dose of SR2508
(1 gm m-2) to be administered one week before the combined
treatment. The use of this lower dose allowed determination
of both dose dependency and the effects of cyclophos-
phamide upon SR2508 pharmacokinetics, using the patient as
their own control. One week later, cyclophosphamide
1 gmm-2 was administered IV over 10 min, and exactly 4 h
later, SR2508 as 30 min or 60 min infusion. The starting dose
of SR2508 was 2.5 gm m-2, a dose which had been tolerable
in the phase I trial of SR2508 as a radiosensitiser. In subse-
quent courses, the same dose and schedule of SR2508 and
cyclophosphamide were administered at three to four week
intervals, without dose escalation in individual patients. Since
definition of the cumulative maximum tolerated dose was of
interest as part of this study, six patients were entered at each
dose level.
Doses of SR2508 were escalated from 2.5 to 15 gm m-2 in
nine escalations. Following the accrual of 28 patients, a
review of the pharmacokinetic data showed that the phar-
macokinetics of SR2508 in individual patients were identical
on weeks one and two. Accordingly, the design was changed
to administer the same dose of SR2508 on weeks one and
two. At 7.2 gm m2, myelosuppression with the combination
of cyclophosphamide and SR2508 became dose-limiting.
Since the myelosuppression was a reflection of the effect of
SR2508 upon cyclophosphamide toxicity, and not solely a
toxicity attributable to SR2508, the dose of cyclophos-
phamide was reduced by 25%, and escalation continued to
the maximum tolerated dose of SR2508. The maximum
tolerated dose was defined as the dose at which over 50% of
patients had grade 3 or 4 toxicity attributable to SR2508.
Pharmacokinetic sampling
Blood samples (5 ml) were drawn into Vacutainer tubes con-
taining no anticoagulants, and centrifuged after 20 min.
Serum was separated and stored at - 40°C. Blood samples
were obtained at baseline (before infusion), and at 0.25, 0.5,
1, 1.5, 2, 4, 8, 12, 24, 36, 48, and 72 h after drug administra-
tion. Urine was collected in four hour aliquots for 24 h, and
in 12 h aliquots subsequently for a total of 48 h after each
dose. Urine collections were kept on ice in the dark. Aliquots
(5 ml) from each specimen were stored at - 40°C for later
analysis.
Analytical method
SR2508 concentrations in plasma and urine were measured
by the method of Workman et al., pp.291-361, (1983).
Briefly, samples were thawed and deproteinised with
methanol, and the supernatant evaporated to dryness under a
stream of N2 at room temperature. The residue was
resuspended in mobile phase and injected (by way of a
Hewlett Packard automated injector) onto a C18 Versapack
column (30 x 4.1 mm ID) in a Hewlett Packard HP1090
HPLC system. The mobile phase was 5% methanol in water;
SR2508 had a retention time of 4 min. Detection was by uv
absorbance at 323 nm; peak heights were integrated and
stored by a HP 85-B data system, and concentrations deter-
mined by reference to a standard curve which was run with
each batch of samples. No other nitro-containing species
have been detected in plasma, urine, or tissue samples using
this analytic procedure. The day to day coefficient of varia-
tion (CV) less than 10% from 0.1 to 50 lig ml-', and the
within-day CV was <4%. The lower limit of detection was758 P.J. O'DWYER et al.
50 ng ml- ', and the detector response was linear up to
50SLg ml1.
Biochemical assaysfor GSH and GSH transferase
GSH and GSH transferase were measured in peripheral
mononuclear cells obtained from samples of whole blood
(5 ml) layered over Ficoll-Hypaque and centrifuged at 400 g
for 15-20min. Blood samples were obtained at baseline, 1,
2, 4, 8, 12, 24 and 48 h after drug administation. In selected
patients, tumour biopsies were obtained at baseline, 12 and
24 h following treatment. Biopsy samples were obtained by
surgical excision, and the tissue was stored at - 70°C. At the
time of assay, red cells, peripheral mononuclear cells, and
tissue samples were thawed, resuspended in phosphate
buffered saline, and homogenised using a Polytron (for tissue
samples) or sonication (for red blood cell and peripheral
mononuclear cell samples). GSH transferase was assayed
spectrophotometrically by measuring the formation of a con-
jugate of glutathione and l-chloro-2,4-dinitrobenzene
(CDNB) as described by Habig and Jakoby, 1981. GSH was
measured by a modification of the method of Griffith et al.,
in which the rate of formation of a GSH conjugate of
5,5'-dithio-bis (2-nitrobenzoic acid) (DTNB) is determined
spectrophotometrically (Griffith, 1980). Observed GSH and
GSH transferase levels were normalised to protein content
using the Bradford assay Bio-Rad, Richmond, VA).
Data analysis
Pharmacokinetic analysis of each patient's plasma samples
was carried out using NONLIN84 (Statistical Associates,
Lexington, Kentucky). For SR2508, the plasma levels best fit
a two-compartment open model, represented by the equation:
Ct = Ae-'t + Be-t
incorporating a correction factor for length of infusion. Sam-
ple weighting of 1/y2 was used throughout. The area under
the plasma concentration-time curve was obtained by integra-
tion of the fitted equation. Clearance and volume parameters
were calculated by standard methods (Gibaldi & Perrier,
1982).
The pronounced inter-patient variability of biochemical
results led to difficulty in applying standard regression
analysis methods to the GSH and GSH transferase data.
Because of the lack of a clear dose-response relationship, the
pooled data from all available patients were analysed
separately for both the first and second courses to allow an
assessment of the extent and time-course of the observed
changes. The data are described in terms of median effects as
a function of time after SR2508 dosing. Comparisons of
values of GSH and GSH transferase at all time points were
made with baseline values using the Wilcoxon 2-sample test
(two-tailed). We did not attempt to account for the many
tests completed on the data. Evidence for relationships
between various clinical, pharmacokinetic, and biochemical
parameters were sought using Spearman's rank correlation
test.
Table I Phase I Study SR2508/cyclophosphamide: dose levels
Week 2
Week 1 Cyclophosphamide 2 Week 2 Number of
Level SR2508 dose SR2508 dose patients
1 1 1000 2.5 6
2 1 1000 3.25 6
3 1 1000 .4 6
4 1 1000 5.5 6
5 1 1000 7.2 3
6 7.2 1000 7.2 3
7 9.4 750 9.4 6
8 12.2 750 12.2 5
9 15 750 15. 3
Table II Demographic characteristics of the study population
Patients entered/evaluable 47/46
Male/female 28/19
median age (range) 60 (35-76)
Performance status 0 14
1 26
2 7
Prior therapy
Chemotherapy 17
Chemotherapy + radiation 21
Biologicals + chemotherapy 4
Biologicals + radiation 1
No prior treatment 4
Tumour type
Colon 24
Lung 8
Ovarian 2
Other 13
patients were minimally symptomatic. Most of the patients
were heavily pretreated and had diseases that are generally
refractory to alkylating agents. Patients received a median of
two cycles of treatment (range 1-11).
Myelosuppression
As expected, a major toxicity of treatment with SR2508 and
cyclophosphamide was myelosuppression. Nadir counts were
usually observed on dl4 with recovery by d21, and neut-
rophils were affected almost exclusively: thrombocytopenia
was sporadic. These characteristics implicate cyclophos-
phamide as the major contributor to this toxicity. Unex-
pectedly, the severity of leukopenia and neutropenia was
related to the dose of SR2508: at the doses at which cyc-
lophosphamide was administered at 1 gm-2 there is a clear
increase in the grade of leukopenia with increasing SR2508
dose in the range 2.5 to 7.2 g m-2 (Table III). At higher
SR2508 doses, with cyclophosphamide 750 mgm2, myelo-
suppression was tolerable. When neutropenia was analysed as
the per cent decrease in neutrophil count (i.e. [pretreatment-
nadir]/pretreatment) it was strongly correlated with SR2508
dose (P<0.01) at SR2508 doses up to 7.2 gm-2 with cyclo-
phosphamide 1000 mgm2 (Figure 1). This correlation was
less pronounced at cyclophosphamide doses of 750 mgm-2
Results
Forty-seven patients received 96 courses (range 1 to 11,
median 2) of cyclophosphamide in combination with SR2508
between March 1987 and May 1989. The dose-escalation
schema as modified by clinical and pharmacologic results is
shown (Table I). At 7.2 g m-2 of SR2508 and 1 gm-2 cyc-
lophosphamide, dose-limiting myelosuppression required a
25% reduction in the dose of the latter. At this level too,
analysis of the pharmacokinetic results to that time showed
no evidence of dose-dependency; accordingly the dose on the
first week (without cyclophosphamide) was increased to equal
that given with the alkylator.
The demographic characteristics of patients treated on this
study are shown (Table II). Eighty-five per cent of the
Table III Neutropenia following SR2508 and cyclophosphamide
administration
Cyclophos-
SR2508 phamide
dose dose Number of Neutropenia-grade
(gm-2) (mgm-2) patients 0 1 2 3 4
2.5 1000 6 4 0 0 1 1
3.25 1000 6 1 0 3 2 0
4.2 1000 6 2 0 1 1 2
5.5 1000 6 2 0 1 0 3
7.2 1000 7 1 0 0 3 3
9.4 750 6 2 1 0 1 3
12.2 750 6 1 0 1 1 3
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Figure 1 Relationship between the per cent decrease in neut-
rophil count ([pretreatment-nadir]/pretreatment) and SR2508
dose in patients treated with SR2508 and cyclophosphamide
I gmm-2.
and higher SR2508 doses. The per cent decrease in platelet
count (not a clinically significant toxic effect) was not detec-
tably related to SR2508 dose.
Doses of cyclophosphamide were not generally reduced in
the face of myelosuppression unless recovery was particularly
delayed. In four patients with grade 3 or 4 neutropenia, a
50% dose reduction ameliorated toxicity on subsequent
courses. Of a total of 19 patients who developed grade 4
neutropenia, there were only three episodes of sepsis: one of
these patients who also had Grade 4 thrombocytopenia,
developed a fever, fell at home, and died of an apparent
intracerebral hemorrhage. The other two patients recovered
uneventfully.
Among eight patients who received three or more courses
of SR2508 and cyclophosphamide, there was no evidence of
cumulative myelosuppression.
Neurotoxicity
While myelosuppression was largely attributed to cyclophos-
phamide with a possible contribution of SR2508, the most
important and dose-limiting toxicity attributable to SR2508
itself was neurotoxicity. From previous work with
misonidazole, it was anticipated that central neurotoxicity
(confusion, hallucinations, etc) might limit the single dose of
SR2508. Peripheral neurotoxicity, manifest as a sensory
motor neuropathy, was expected to limit the cumulative dose
of SR2508. However the predominant neurologic manifesta-
tion was a novel sensory neuropathy in which a constellation
of symptoms followed SR2508 administration as a single
agent or in combination with the alkylating agent. At doses
> 9.4 g m2, a syndrome of acute pain and tingling,
radiating symmetrically down the extremities from the hip or
shoulder girdles began from four to twelve hours after treat-
ment. The severity of this paraesthesia-dysaesthesia pain syn-
drome was dose-related and was dose-limiting at 15 gm-2
(Table IV). At this dose, two of three patients required high
doses of morphine for pain relief. Resolution of symptoms
occurred within 12 to 18 h, leaving no long term sequelae;
subsequent sensory examinations were normal. The severity
of these symptoms appeared to diminish with repeated dos-
ing.
There was no evidence of central neurotoxicity at any dose
studied in this trial. At doses higher than 7.2 g m2, patients
were evaluated before, and at various times after SR2508
administration using the 'mini-mental' test of cortical func-
tion (Folstein et al., 1975). Patients' scores did not change in
the 24 h after treatment. Six patients experienced anxiety
and/or depression in the weeks after treatment.
Cumulative neurotoxicity is more difficult to assess in a
Phase I study, since patients do not usually receive a large
number of courses. In the Radiation Therapy Oncology
Group studies, considerable heterogeneity among patients is
reflected in the maximum tolerated total dose of SR2508
which ranged from 21 to 40.8 g m-2 (Varnes et al., 1990). In
this study 15 patients were treated with cumulative doses of
SR2508 > 21 g m-2. The maximum total dose administered
was 60 g m-2. Table V shows the incidence of peripheral
neuropathy (vincristine-like chronic sensory impairment, as
opposed to the acute phenomenon observed within hours of
SR2508 administration) among groups of these patients. It
seems clear that patients tolerate a total dose of up to
40 gm-2 without difficulty. Small numbers at higher doses
preclude a confident prediction of the cumulative maximum
tolerated dose. This should be explored further in Phase II
trials.
Other toxicity
Thirty-one of the 47 patients (66%) had nausea and vomiting
following SR2508 administration. In all but three, symptoms
were easily controlled with standard antiemetics, and treat-
ment was only required during the 24 h following drug
administration. In three patients, grade 3 vomiting prevented
adequate oral intake: in these -patients too, the symptoms
resolved by 24 h.
Mild to moderate hepatic toxicity (as evidenced by in-
creased liver enzymes or bilirubin) was also identified in 13
patients (28%). Many of those affected had liver involvement
with tumour. Neither the nausea/vomiting nor the hepatic
toxicity were dose-related.
Pharmacokinetics
Full pharmacokinetic studies were performed with and with-
out cyclophosphamide in each patient. A typical plasma
concentration-time curve is shown (Figure 2). The mean
pharmacokinetic parameters at SR2508 doses from 2.5 to
7.2 gm2 are presented (Table VI). These patients received
an initial SR2508 dose of 1 g m-2. In all patients, the plasma
concentration-time curve fit a two-compartment open model.
The harmonic mean terminal half-life was remarkably repro-
ducible among patients, varying from 5.1 to 5.8 h. The area
under the concentration time-curve was linearly correlated
with dose (r = 0.88, P = 0.0001) (Figure 3).
Since the sensitising efficacy of SR2508 depends upon its
penetration of tissue compartments, we sought an estimate of
overall tissue concentrations by considering the peripheral
compartment represented in the kinetic model. Figure 4
Table IV Paresthesia-dysesthesia syndrome following SR2508 and
cyclophosphamide administration
SR2508
dose Number of Acute neurotoxicity-grade
(gm-2) patients 0 1 2 3 4
2.5 6 3 2 1 0 0
3.25 6 5 0 1 0 0
4.2 6 4 1 1 0 0
5.5 6 3 1 2 0 0
7.2 7 7 0 0 0 0
9.4 6 2 1 3 0 0
12.2 5 0 2 3 0 0
15.0 3 0 0 1 2 0
Table V Cumulative vincristine-like neuropathy associated with
SR2508 administration
Grade
Total dose (gm-2) No. of patients 0 1 2 3
0-10 22 19 2 1
11-20 10 8 2
21-30 6 1 2 1 2
31-40 4 2 2 -
41-50 4 2 1 - 1
51-60 2 - - - 2
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Figure 2 Plasma concentration time-curve from a patient treated
with SR2508 9.4 g m-2.
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Figure 4 Simulation of SR2508 concentration in plasma (central
compartment, solid line) and tissue (peripheral compartment,
dashed line) following a 5.5 g m-2 dose. Concentrations were
simulated using mean values of the first-order transfer and
elimination constants obtained from non-linear regression
analysis using a two-compartment body model of six patients at
this dose level.
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Table VII Pharmacokinetics of SR2508 alone and in combination with 750mgm2 cyclophosphamide
Level VI 9.36gm-2 Level VII 12.2gm-2 Level VIII 15gm-2
Alone + CTX Alone + CTX Alone + CTX
n 5 5 6 6 3 3
Serum parameters
AUC, tLg x h ml-' 3933 ± 457a 3397 ± 448 3541 ± 359 3372 ± 386 5003 ± 214 4114 ± 165
tl/2a, min 130b 21.8 22.0 19.3 21.2 18.3
(7.43-21.7) (16.5-27.5) (15.5-28.7) (14.0-23.3) (12.8-38.6) (16.2-22.7)
t1/2P, h 5.6lb 5.53 4.30 4.24 4.71 4.68
(4.10-7.72) (3.65-7.66) (3.57-5.21) (3.71-5.21) (4.06-5.50) (4.35-5.21)
Cl,O,ml minm- m-2 42.2 ± 5.65 51.1 ± 10.0 60.4 ± 5.87 64.7 ± 7.84 48.8 ± 2.77 61.0 ± 2.36
Urine parameters
C1renai, ml min-'m-2 31.0 ± 3.94 39.2 ± 8.54 48.1 ± 6.48 57.0 ± 7.07 41.6 ± 0.74 44.1 + 2.06
% Cl0,t 73.5 76.7 79.6 88.1 85.3 72.3
Volumes of distribution
Vc, 1 m2 6.61 ± 0.63 7.80 ± 0.91 8.01 ± 0.50 7.69 ± 0.50 8.19 1.07 8.15 0.43
Vss. Im-2 18.6± 0.8 20.6±0.7 18.7±0.8 19.5± 1.1 17.6 1.0 21.4 0.6
V0, lm-2 20.4± 0.9 23.9± 1.3 22.3± 1.1 23.4± 1.1 20.0± 1.1 24.8 0.4
aValues are mean ± s.e.m. bValues are harmonic mean (range).
shows the model-predicted drug concentrations in the peri-
pheral compartment. While these levels cannot be used to
describe actual concentrations in a particular organ, they
provide an estimate that may be of value in selecting doses
for sensitising regimens. It may be seen that doses > 5.5 g
m 2 result in levels ) 2 mM, a concentration sufficient to
sensitise cells in many hypoxic systems (Brown & Workman,
1980).
Volumes of distribution were similarly reproducible among
groups of patients. The volume of the central compartment
approximated that of extracellular fluid, while the steady-
state volume of distribution was consistent with drug dist-
ribution through the total body water, with minimal tissue
binding.
The total-body clearance range from 46.6 to 94.0 ml min-'
m-2, and was not dose-related. Renal clearance accounted
for approximately 70% of total body clearance, and about
70% of the dose was found in the urine in the 48 h collection
period. Metabolites of SR2508 were not detected using this
analytical method: no additional peaks were found on the
chromatograms of serum or urine. The extent to which
metabolism or hepatic excretion of SR2508 contributes to
drug removal is unknown at this time but would be expected
to account for the difference between total body clearance
and renal clearance (30%).
The effect of cyclophosphamide on SR2508 pharmaco-
kinetics may best be analysed in the patients who received
the same dose with and without the alkylator (i.e. patients at
7.2, 9.4, 12.2 and 15 gm2). In Table VII are presented the
principal pharmacokinetic parameters observed in these
patients. Pretreatment with cyclophosphamide does not
markedly influence the kinetics of SR2508.
N 200.0-
E
.E 150.0-
E
(D
co 100.0-
G) .
> 50.0-
O0
I 0.0 -
0.0 25.0 50.0 75.0 100.0 125.0 150.0 175.0 200.0
Creatinine clearance (ml min-1)
Figure 5 Total body clearance of SR2508 as a function of
creatinine clearance.
The relationship between renal function and SR2508 dis-
position was analysed by plotting creatinine clearance
(derived from a nomogram) against the total body clearance
of SR2508 (Figure 5). As anticipated from the SR2508
urinary excretion data, the relationship was highly significant
(r = 0.626, P = .0001).
Relationships between pharmacokinetic parameters and
toxicity showed several positive correlations. The total body
clearance of SR2508 (and therefore renal clearance) was
significantly related to both white cell and neutrophil toxicity
(P<0.005) (Figure 6). Since this level of significance is much
lower than that for either area under the concentration-time
curve or SR2508 dose, it may be that the renal clearance of
SR2508 and that of active metabolites of cyclophosphamide
are related.
Biochemical results
SR2508 at doses as low as 1 g m-2 inhibits GSH transferase
activity in peripheral mononuclear cells, but not in red cells
(data not shown), by over 50%. The reason for this dis-
crepancy is not clear, but may relate to the higher concentra-
tion of GSH in red blood cells. Depletion of peripheral
mononuclear cell GSH levels parallels the inhibition of GSH
transferase, which suggests a common mechanism.
The mean baseline value for GSH in peripheral mono-
nuclear cells was 0.265 (± 0.037, SEM) nmol-' mg protein
among 42 patients. When measured one week after the initial
SR2508 dose, these values were unchanged at 0.254 (± 0.034,
SEM) nmol mg-' protein. The baseline GSH transferase
activity was 1.17 (± 0.14, SEM) nmol min' mg-' protein
among 43 patients. This value too was unchanged by SR2508
administration at 1.07 ( 0.15, SEM) nmol min mg pro-
tein in week 2.
Because of pronounced inter-patient variability, no dose-
response relationship for GSH transferase inhibition or GSH
depletion in peripheral mononuclear cells could be discerned.
Visual inspection of the data showed that the values for both
GSH and GSH transferase declined after SR2508 treatment,
followed by recovery. Using the Wilcoxon two sample test
(two-tailed), the values for GSH at 8 and 12 h were
significantly different from those at other times (P = .001).
The GSH transferase values at these times were also different
from those at other times (P = .004).
To allow an assessment of the time-course of these effects,
the data from all the patients were pooled. Figure 7 shows
the median change in the values for the first and second
courses respectively. Following the first course (SR2508
alone) 24% inhibition of GSH transferase activity compared
to control was observed at 12 h, with recovery by 24 h.
Following the second course (SR2508 and cyclophos-
phamide) a more profound effect (about 40% inhibition)762 P.J. O'DWYER et al.
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Figure 6 Total body clearance of SR2508 with cyclophosphamide 1000 mg m-2 vs leukopenia (Panel a) and neutropenia (Panel b)
and total body clearance of SR2508 with cyclophosphamide 1000 mg m-2 (a and b) and cyclophosphamide 750 mg m-2 (c + d) vs
leukopenia (a + c) and neutropenia (b + d). The percent decrease in blood counts is calculated from (pretreatment count-nadir
count/pretreatment count) and expressed as a percentage.
reflects the contribution of both drugs, but with a similar
time-course to that observed with SR2508 alone.
More marked effects were observed on the GSH content of
peripheral mononuclear cells in this analysis. A decline in
GSH concentration by 50% was found at 12 h following
SR2508 treatment, with recovery by 24 h. Addition of cyc-
lophosphamide did not result in a markedly greater degree of
GSH depletion (61% of control). The changes in GSH trans-
ferase activity and GSH content at the foregoing but not
other time-points were significantly different from baseline
(P< .05).
There was no relationship between the observed bio-
chemical changes in peripheral mononuclear cells and either
clinical toxicity or pharmacokinetic parameters.
We obtained biopsies of tumour tissue before and at 12
and 24 h after SR2508 administration in three patients (Table
VIII). Each received a dose of 9.4 to 12.2 g m-2 of SR2508.
The results of the GSH transferase and GSH analyses are
concordant with the peripheral mononuclear cell data: pro-
nounced interpatient variability is apparent. One patient had
no evidence of a biochemical effect, while one had a modest
and one a profound change in the measured activities. In
these patients, pharmacokinetic differences did not explain
the variability.
Discussion
In this Phase I study, the maximum tolerated dose of SR2508
was sought based on preclinical evidence in vitro and in vivo
that sensitising efficacy is a function of concentration or dose
(Clement et al., 1980; Brown et al., 1981). Indeed, the failure
of misonidazole to exhibit significant enhancement of
alkylator efficacy has been attributed to an inability to yield a
Table VIII GSH and GSH transferase determination in tumour biopsies of patients treated
with SR2508
GSH transferase (% Control) GSH (% Control)
Patient IE WM AG IE WM AG
Baseline 100 (46.7)a 00(42.1) 100(21.5) 100(6.1) 100(15.2) 100(2.37)
12 h 129 59 21 143 51 20
24 h 75 66 94 124 91 200
aValues in parentheses present control GSH transferase specific activity expressed as
nmol mg-' protein min-' or GSH concentrations expressed as nmol mg-' protein.
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clinically-important dose-modifying factor (Coleman et al.,
1988). (The dose-modifying factor is the ratio of doses or
concentrations of a cytotoxic drug required to achieve a
target effect in the presence vs the absence of the sensitising
agent). Based on in vitro models, a dose-modifying factor of
about 1.5 may be anticipated with SR2508 concentrations of
>2 mM (428jig ml-'); our analysis of drug concentrations in
the peripheral compartment suggests that such levels were
achieved at doses > 5.5 g m-2 in this study. Such doses
would be expected to sensitise hypoxic cells to alkylating
agents, and should be tested in Phase II trials. However,
doses higher than 7.2 g m-2 should probably not be used in
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regimens using conventional toxicity criteria, since potentia-
tion of cyclophosphamide myelosuppression may require
dose-reduction of the alkylating agent.
The maximum tolerated dose of a single dose of SR2508
was found to be 12.2 gm-2. Above this, neurotoxicity was
dose-limiting. The 'paraesthesia-dysesthesia syndrome' we
have described appears to be unique to SR2508 among 2-
nitroimidazoles, and is not described, to our knowledge, in
response to other neurotoxins. The syndrome represents an
acute, reversible sensory neuropathy. As with the biochemical
effects, the onset of this syndrome was delayed, reaching a
peak at 8-12 h following drug administration. This time
a
b
- I I I I I
0.0 10.0 20.0 30.0
Time (hours)
40.0 50.0 60.0764 P.J. O'DWYER et al.
c
._
4
0
0)
E
E
C
0
I
c)
(9
c
._
0) a 7
Q
E
7
EC
U) '
(/)
(9
60.0
30.0
Time (hours)
Figure 7 Median (and upper and lower quartile) values for GSH content and GSH transferase activity in the peripheral
mononuclear cells of patients treated with SR2508 alone (Cycle 1) (Panels a and b) and cyclophosphamide followed by SR2508
(Cycle 2) (Panels c and d).
course is consistent either with inhibition of intracellular
processes eventually resulting in depletion of their product,
or with the formation of a metabolite that may itself be
neurotoxic.
SR2508 was chosen for development based on its low lipo-
philicity (Brown & Workman, 1980). As predicted, SR2508
causes little central neurotoxicity, though at many of the
doses used in this study, mild psychological effects (anxiety,
depression) were noted. Objective cortical impairment did not
occur. The greater central effects reported with misonidazole
suggest that differences in the rate of drug accumulation in
the brain vs the peripheral nervous system may be responsi-
ble for this altered pattern of toxicity. Consistent with the
delayed effects of SR2508 on the nervous system, the onset of
nausea and vomiting (which occurred in the majority of
patients) pursued a time course similar to that of thePHASE I TRIAL OF SR2508/CYCLOPHOSPHAMIDE 765
paraesthesia-dysesthesia syndrome. Similar findings have
been reported in a Phase I trial of this combination from the
University of Wisconsin (Bailey et al., 1991).
Coleman and colleagues have demonstrated a relationship
between the total area under the concentration-time curve of
SR2508 and the probability of developing a chronic peri-
pheral sensory neuropathy following repeated small doses of
the drug (Coleman et al., 1987). In the current study, the
incidence of this type of sensory neuropathy associated with
high cumulative doses of SR2508 was low. Total doses up to
60 g m-2 were tolerated by two patients. These limited data
suggest that the development of a peripheral sensory
neuropathy may relate both to the AUC and to the schedule
of administration: higher cumulative doses may be tolerated
using intermittent schedules such as this. Future phase II
studies of SR2508 will clarify the cumulative dose tolerance
of the drug on this schedule, and describe its relationship to
pharmacokinetic parameters.
The relationship of myelosuppression following combined
treatment with SR2508 and cyclophosphamide to SR2508
dose, and more accurately, to SR2508 clearance, is of some
interest. An obvious interpretation is that SR2508 (not a
known myelotoxic agent) may potentiate the toxicity of cyc-
lophosphamide to bone marrow stem cells. This may occur
as a result of GSH depletion in oxic cells as occurred in
peripheral mononuclear cells; enhanced toxicity ofcyclophos-
phamide (Grau et al., 1990) and other alkylators (Durand &
Chaplin, 1987; Horsmann et al., 1989) to oxic cells is well-
described in vivo and in spheroids. Allalunis et al. have
shown in addition that a proportion of normal marrow cells
exist in a hypoxic environment (Allalunis et al., 1983). Sen-
sitisation of these cells by SR2508 may contribute to the
enhancement of myelosuppression observed.
An alternative explanation is suggested by the phar-
macokinetics. The close relationship between SR2508 and
creatinine clearance may also exist between renal function
and the plasma clearance of the active metabolites of cyc-
lophosphamide. Thus, indirectly SR2508 clearance and
clearance of alkylating species may be related. However, a
potentiating effect of SR2508 at the level of the marrow is
supported by the dose-related enhancement of marrow tox-
icity.
As others have reported, the pharmacokinetics of SR2508
are remarkably uniform among patients. Our results are
almost identical to those of Bailey et al. (Bailey et al.,
1991). Our studies of SR2508 content in tumour biopsies
confirm those of others showing that tumour drug levels are
comparable to those of simultaneously obtained plasma
levels (Coleman et al., 1984). since sensitisation by SR2508
requires its intracellular metabolism, activities of the enzymes
mediating one-electron reduction are potentially important
determinants of drug effect. Individual variation in sensitising
efficacy may thus depend upon the capacity of the hypoxic
tumour tissue to metabolise SR2508 to its one-electron
reduction intermediates. The nitroreductase activity of
tumours was not characterised in this study, but may be an
important determinant of and predictor for response.
Such variation may explain the biochemical findings in
peripheral mononuclear cells. Inhibition of GSH transferase
and depletion of GSH followed the administration of SR2508
in a majority of the patients. Effects were observed at the
lowest doses of SR2508, but inter-patient variability was
pronounced: in some patients no biochemical changes occur-
red. As a result, no clear relationship to dose could be
established. Such a finding often indicates population
variability in drug handling, but since the proportion of
SR2508 eliminated non-renally is small (over 70% unchanged
in the urine) a pharmacogenetic pattern is not evident from
the pharmacokinetic data. Future studies will address the
role of metabolic phenotype in determining the biochemical
effects of SR2508.
The medians of the pooled data from the 47 patients
showed a clear and significant trend to a nadir of GSH
content and GSH transferase activity at 8-12 h after dosing.
A similar, delayed depletion of GSH was observed in murine
tumours and normal tissues following SR2508 administration
i.p. (Horsmann et al., 1989). In both species the time of drug
administration varied throughout the day so that a circadian
variation alone is unlikely to be responsible for the observed
effects. The mechanism of the depletion of GSH is not
known. A metabolite which has been identified in vitro, but
not hitherto in vivo, in the GSH conjugate of SR2508 (Var-
ghese & Whitmore, 1986). Our current studies are directed to
the further investigation of this derivative (O'Dwyer et al.,
1992).
Finally, it was hoped that the time course of biochemical
changes in tumour tissue would provide a guide to the
scheduling of SR2508 with the alkylating agent. The three
patients in whom biopsies were obtained sequentially show a
pattern of heterogenity similar to that observed in the studies
of peripheral mononuclear cells. Inhibition of GSH trans-
ferase and depletion of GSH at 12 h in two of the three
patients, with recovery of 24 h (in GSH levels at least) sug-
gest that maximal biochemical effects in tumour probably
occur with a time course similar to those in peripheral
mononuclear cells. The time course of the biochemical
changes and of certain of the toxicities (e.g. nausea and
vomiting, and paresthesia-dysesthesia) indicate that many of
the effects of SR2508 are exerted 8-12 h after dosing. Since
some of the preclinical in vivo models support pretreatment
with the nitroimidazole, these data suggest to us that
modification of the schedule of administration for Phase II
trials will be appropriate. Unlike the schedule reported here
or the simultaneous administration of these drugs in the
study of Bailey et al., 1991, a schedule of SR2508 and
cyclophosphamide which would administer the sensitiser first,
followed 4 h later by cyclophosphamide would effectively
allow an 8 h interval between SR2508 administration and the
appearance of maximum alkylating activity. It is this
schedule that might best be tested in Phase II trials of
SR2508 as a sensitiser of alkylating agents.
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